Menopause is defined as the permanent cessation of menstruation due to loss of ovarian follicular function. It is characterised by hypoestrogenism and increased gonadotropins, resulting in systemic symptoms.
Perimenopause is the time from onset of cycle irregularity to 12 months after the final period.
In Australia:
the average age of menopause is 51.5 years (range is 45 to 55 years)
up to 10% experience early menopause (<45 years)
about 1% experience premature ovarian insufficiency (POI) (before age 40)
The primary cause of menopause is age-related ovarian follicle depletion. Other factors which may contribute to earlier timing of menopause include:
genetic factors (eg familial POI)
iatrogenic causes (eg chemotherapy, oophorectomy)
autoimmune disease
smoking (advances menopause onset by 1–2 years)
lower body mass index
lower socioeconomic status
Typical symptoms include:
vasomotor symptoms (VMS) (hot flushes, night sweats)
urogenital symptoms (vaginal dryness, irritation, dyspareunia, urinary urgency)
psychological (mood disturbance, anxiety, irritability)
sleep disturbance
decreased libido
cognitive symptoms
Bleeding post-menopause
Unexplained weight loss
Severe depression or suicidality
Age <45 (consider possibility of POI)
Thyroid dysfunction: symptoms overlap with vasomotor and mood changes
Depression/ anxiety: may occur independently
Drug-induced symptoms: eg from tamoxifen, SSRIs
For women ≥45 years, diagnosis is clinical.
Consider investigations if:
aged <45 with symptoms (FSH, estradiol on two occasions, four weeks apart)
differential diagnosis is uncertain (TSH, Hb, ferritin, blood glucose)
Educate about the normal menopausal transition
Discuss expectations, quality of life, and treatment goals
Encourage lifestyle modification: smoking cessation, reduced alcohol, healthy weight, regular exercise
Menopausal hormone therapy (MHT)
MHT is the most effective treatment for vasomotor symptoms and urogenital atrophy. It also helps prevent bone loss and may improve sleep, mood, and joint pain in some women.
Moderate to severe vasomotor symptoms
Urogenital symptoms not responsive to non-hormonal options
Premature ovarian insufficiency (continue until at least age 50)
Prevention of osteoporosis in symptomatic women with low bone density
History of hormone-sensitive cancer (eg, breast, endometrial)
Unexplained vaginal bleeding
Active or past venous thromboembolism
Uncontrolled hypertension
Liver dysfunction
Combined MHT (oestrogen + progestogen): for women with an intact uterus to reduce endometrial hyperplasia risk
Oestrogen-only MHT: for women post-hysterectomy
Oestrogen can be delivered orally or transdermally
transdermal oestrogen (patch, gel) is preferred in women at higher risk of thromboembolic events or with metabolic/liver disorders
patients with history of migraine may also benefit from transdermal oestrogen delivery as it maintains a more stable delivery of oestrogen, avoiding the fluctuating serum oestradiol levels, which can be a trigger for the exacerbation of migraine in perimenopausal years
Progesterone can be delivered either via an intrauterine device (Mirena) or orally
micronised progesterone is the preferred oral choice, as it is associated with a more favourable breast safety profile compared to synthetic progestins
In women who are still having regular cycles, oral progesterone needs to be delivered cyclically (usually 14 days on, 14 days off) or the patient may experience breakthrough bleeding. For women who are postmenopausal, continuous progesterone is appropriate
It is important to advise women that MHT does not provide contraception due to the lower doses of oestrogen and progesterone (the exception would be women who are using a Mirena device for endometrial protection). For women who are still having periods, a low-dose combined oral contraceptive pill may be an appropriate option to both manage their symptoms and provide adequate contraceptive cover
Start low and titrate to symptom relief
No standard duration; use the lowest effective dose for the shortest period consistent with treatment goals
Annual review is essential to reassess risks, benefits, and treatment goals
Combined MHT is associated with a very small increase in breast cancer risk, increasing with age at initiation and duration of use
Oestrogen-only MHT may have a lower breast cancer risk compared to combined MHT
Oral MHT carries a higher risk of thromboembolism; transdermal preferred in higher-risk women
In general, for women without other complications, initiation of MHT has the most benefit with the lowest risk when started below the age of 60, or within 10 years of menopause. Annual review should continue to occur to determine need for ongoing use, with risks of complications increasing with age and duration of use
Regular review of BMI, symptom control and breast health
Regular review of blood pressure and other CV risk factors
Mammography and cervical screening per national screening guidelines
Annual review of ongoing need for MHT, particularly after 5 years of use
Women with early or surgical menopause are generally advised to take MHT until around the age of 50 years at least for symptom control and long-term health protection
Vaginal oestrogen therapy is effective and safe for urogenital symptoms, including in women with a history of breast cancer (in consultation with oncology)
Tibolone may be considered for women >12 months postmenopause with VMS and low libido
Non-hormonal treatments
Neurokinin-3 receptor antagonists (eg fezolinetant) are a class of non-hormonal medications that modulate thermoregulatory pathways in the hypothalamus to reduce moderate to severe VMS and have recently been approved by the TGA for use in menopause
Other non-hormonal medications which, although they have evidence to support their use for VMS, are prescribed off label, include SSRIs/SNRIs (eg, venlafaxine, paroxetine), gabapentin, pregabalin, and oxybutynin
CBT can help both menopausal symptoms and mood
Limited evidence for herbal remedies (eg, black cohosh, soy)
Yoga and hypnosis show benefit in small trials
Annual review of symptom control and therapy risks
Monitor BP, weight, breast health, and discuss screening adherence
Diagnostic uncertainty (eg atypical presentation, persistent symptoms)
Suspected POI or early menopause
Failure of primary care management
History of hormone-sensitive cancer or complex medical background
Symptoms typically last 4–7 years; 10% experience symptoms beyond 10 years. Untreated urogenital symptoms often persist. MHT improves quality of life and bone health but must be used judiciously. Patients may need to consider a trial of gradual reduction of their medication to assess whether their symptoms persist in the absence of treatment.
The Royal Australian and New Zealand College of Obstetricians and Gynaecologists. Managing menopausal symptoms. 2020. (last accessed June 2025).
Australasian Menopause Society. Non-hormonal Treatments for Menopausal Symptoms. 2024. (last accessed June 2025).
S. R. Davis, S. Taylor, C. Hemachandra, K. Magraith, P. R. Ebeling, F. Jane &
R. M. Islam (2023) The 2023 Practitioner’s Toolkit for Managing Menopause. Climacteric.2023; 26(6):517-536.
After reading the clinical summary above and reviewing the references, complete the quiz to gain 30 minutes of EA CPD and 30 minutes of RP CPD.
You can either self-report CPD to your CPD home, or Medcast will track your learning via your personal CPD Tracker and you can download and report these points once a year. See our CPD Tracker FAQ.
Please log in or sign up for a free Medcast account to access the case study questions and achieve the CPD credits.
The Medcast medical education team is a group of highly experienced, practicing GPs, health professionals and medical writers.
Become a member and get unlimited access to 100s of hours of premium education.
Learn moreDiagnosing cervical myelopathy in primary care can be challenging due to its gradual onset and symptom overlap with other neurological conditions. This FastTrack fact sheet helps to clarify the role of GPs, including red flags for referral, investigations to order, and when it’s appropriate to monitor. 30mins each of RP and EA CPD available with the quiz.
Periodontitis is related to some unexpected comorbidities, including diabetes and cardiovascular disease. This FastTrack describes the role of the GP in the diagnosis and management of this dental disease. Earn 30mins each of RP and EA CPD with the quiz.
Carpal tunnel syndrome (CTS) is one of the most common upper limb conditions. This FastTrack activity provides a concise summary of the diagnosis and management of CTS, including the use of the CTS-6 diagnostic tool and when to refer for surgical intervention. 30min each of RP and EA CPD available with the quiz.